Prospective analysis of the medicine possession ratio of antidepressants in the private health sector of South Africa, 2006 - 2011

F N Slabbert,1 MSc, B H Harvey,1 PhD, C B Brink,1 PhD, M S Lubbe,1 PhD
1 Medicine Usage in South Africa (MUSA), School of Pharmacy, Faculty of Health Sciences, North-West University, Potchefstroom, North West, South Africa
2 Centre of Excellence for Pharmaceutical Sciences, School of Pharmacy, Faculty of Health Sciences, North-West University, Potchefstroom, North West, South Africa
3 Division of Pharmacology, School of Pharmacy, Faculty of Health Sciences, North-West University, Potchefstroom, North West, South Africa

Corresponding author: M S Lubbe (martie.lubbe@nwu.ac.za)

Background. Major depressive disorder (MDD) is a disabling mental illness with high morbidity and mortality rates. Inadequate treatment efficacy, unfavourable side-effect profiles and consequent shortfalls in compliance are major stumbling blocks in its treatment. Non-compliance data in low- to middle-income countries are lacking.

Objective. To investigate the prevalence of antidepressant (AD) non-compliance in the private healthcare sector of South Africa (SA).

Methods. We conducted a prospective cohort study analysing AD medicine claims (N=35 175) for 14 135 patients, obtained from a nationally representative pharmaceutical benefit management company, over a 6-year study period (1 January 2006 - 31 December 2011). The medicine possession ratio (MPR) was used as a proxy to determine compliance with AD medication. Only patients >18 years of age whose treatment had been initiated by a psychiatrist following an appropriate International Classification of Diseases (10th edition) (ICD-10) diagnosis of a mood disorder were included. A patient was considered compliant if the MPR was between ≥80% and ≤110% over a >4-month treatment period.

Results. After the first 4 months, only 34% of patients were compliant. A statistically significant association was found between active ingredient consumed and compliance (p<0.0001). Only 26.2% of patients who received amitriptyline-containing products were compliant, compared with 38.8% and 38.7% for venlafaxine and duloxetine, respectively.

Conclusion. Compliance data collected from pharmacy claims provide a workable estimate of the broader clinical scenario they represent. Although differences between classes of AD were evident, non-compliance was found to be high in the private healthcare environment of SA, comparable with global trends.

S Afr Med J 2015;105(2):139-144. DOI:10.7196/SAMJ.8394

Major depressive disorder (MDD) is a disabling illness affecting people worldwide. The lifetime prevalence for major depression in South Africa (SA) is 9.8%,10 as opposed to 16.7%11 and ~13% for the USA and Europe, respectively.12 MDD not only decreases general health but impairs quality of life, performance at work and at school, and everyday social interactions. MDD poses a substantial risk for suicide,13 with an estimated 15 - 20% mortality rate.14 The economic impact of affective disorders in Europe (major depression and bipolar depression) amounts to EUR106 billion (2004 figures).15 Of this amount, nearly EUR29 billion was spent on direct healthcare costs such as hospitalisation, visits to doctors and drug treatment, whereas EUR77 billion was attributable to indirect costs including premature death, sick leave and workdays lost.16 The economic cost of depressive disorders in the USA in 2007 was estimated to be over USD83 billion,17 with direct and indirect costs on health expenditure of USD26 billion and 57 billion, respectively. Projections done in 2011 indicated that the total annual cost to South Africans living with severe depression and anxiety disorders amounted to USD3.6 billion.16 These estimates suggest either that mental illness has a major economic impact, through the effect of disability and stigma on earnings, or that people in lower income groups are at increased risk of mental illness.

The management of MDD is severely compromised by non-compliance.9 It is recommended that treatment of depression continue for at least 4 - 6 months from the time of remission, to prevent relapse.9,18 This is extended in high-risk patients, those with recurrent illness and/or those with a history of treatment resistance. Several studies have shown that remission rates for compliant patients with depression are higher than for non-compliant patients,14,12 and furthermore that sustained antidepressant (AD) use over 12 - 36 months may decrease the risk of relapse further by up to 70% compared with non-compliant patients.15 In a Spanish study, 56% of patients discontinued their AD treatment within the first 4 months, whereas only 22% maintained satisfactory adherence over a 5-year period.19 Many studies concur that between 30% and 60% of patients do not comply with AD treatment,12,14 and that up to 30% are likely to stop taking ADs within the first month after the start of treatment. In addition, 45 - 60% of patients will have stopped their prescribed treatment by the end of the third month.17,19 Without adequate treatment, patients may experience further relapses of depressive episodes.20 Furthermore, preclinical studies demonstrate that premature discontinuation may evoke a specific sequence of neurobiological events that underlie relapse and treatment resistance.21,22 Compliance and persistence are therefore key concerns in the pharmacological management of MDD.

No studies have investigated AD compliance in low- to middle-income countries. We therefore studied the prevalence of non-compliance with AD treatment in the private healthcare sector in SA, using the medicine possession ratio (MPR) as a proxy for...
patient compliance with ADs, and also looking at possible changes in the prescribed daily dosage (PDD) between compliant and non-compliant patients, and whether class of AD is an additional determinant.

**Methods**

We conducted a prospective, descriptive cohort study analysing nationally representative medicine claims data submitted to a privately owned SA pharmaceutical benefit management (PBM) company. The database included all prescriptions for an AD (Monthly Index of Medical Specialities classification 1.4)[23] for 407 586 patients over a 6-year study period, 1 January 2006 - 31 December 2011.

We extracted data for patient demographics (gender and date of birth) and pertinent prescription information (such as drug trade name, days supplied, dispensing date, quantity of medicine prescribed, initial dose, final dose and ICD-10 code per claim). The quality of data was ascertained by several automated validation processes that were applied by the PBM company. There were no missing data fields in the data sets. The variables ‘birth date’ and ‘dispensing date’ were used to calculate the age of patients on the date of treatment and the number of days between refills.

A study population was selected according to the inclusion criteria illustrated in Fig. 1. The ICD-10 codes are based on the International Statistical Classification of Diseases and Related Health Problems, 10th edition, published by the World Health Organization.[24] In this study the ICD-10 codes F32 (depressive episode) and F33 (recurrent depressive disorder) were used to identify patients with MDD as diagnosed by a psychiatrist. Thereby it was ensured that data were excluded where ADs may have been used for other illnesses, such as amitriptyline for the treatment of chronic pain. The study population was older than 18 years and consisted of a total of 14 135 patients receiving 35 175 AD medicine items dispensed on more than two occasions.

The MPR is a well-established method of calculating drug compliance in pharmacoepidemiological studies, including chronic diseases such as depression,[14] hypertension[25] and osteoporosis[26] and schizophrenia.[27] However, it is important to note that the compliance value obtained from the MPR only gives an indication of the possession of medicine by the patient, and that appropriate consumption of medicine is assumed to ensue from possession. The use of medicine claims data in MPR calculations is helpful in determining whether an association existed between proportions of two or more groups (age groups v. MPR groups). Cramer’s V statistics were used to test the practical significance of this association. The two-sample t-test allowed us to compare the mean MPR of male and female patients. One-way analysis of variance was used to test differences between three or more means and to calculate differences in the adjusted PDD changes between compliant and non-compliant patients. It was operationalised with the general linear model procedure of the SAS Version 9.1.3 system. If a difference was indicated, a Tukey multiple comparison test was performed to determine which groups most significantly influenced the overall difference between groups. Cohen’s d was used to evaluate effect size between means (with d≤0.8 defined as practically significant).[30]

The PDD (in mg) of an AD was calculated by multiplying the number of tablets (or volume of suspension or syrup) dispensed during the treatment period and the strength per tablet (or per mL), divided by the number of days supplied. Possible PDD changes from the first until the last prescription on the database were determined. The correlation coefficient, r, indicated a negative association between the initial PDD and change in PDD (r<−0.5; p<0.0001). Possible PDD changes were therefore adjusted for variations in initial dosage.

The study was approved by the Ethics Committee of North-West University, Potchefstroom Campus, North West Province, SA (NWU-0046-08-A5), and the boards of directors of the PBM. Data were analysed anonymously.

---

**Fig. 1. The inclusion criteria used in the study.**
Results

MPRs of ADs
The mean (SD) age of the patients was 50.4 (15.9) years, 71.1% were women, and 71.1% received AD medication for >4 months (Table 1). The mean MPR of the 35 175 ADs was 98.2% (95% CI 96.6 - 99.9) (Table 2). Only 49.6% of dispensed ADs were associated with an acceptable MPR of between 80% and 110% (Table 1).

No statistically significant differences were found between the MPRs of male and female patients: 98.4% (95% CI 95.4 - 101.4) v. 98.2% (95% CI 96.2 - 100.1) (Table 2). Patients older than 60 years had a lower MPR than those aged 18 - 40 years (p=0.0169) (Table 2).

Table 2 clearly indicates that the treatment period had a statistical (p=0.0001) and practically significant (d=0.8) influence on the MPR of ADs. An abnormally large number of patients were noted to be on treatment for <30 days (255.4%; 95% CI 235.7 - 275.1). This increase in MPR was also practically significant compared with patients on therapy for between 30 and 120 days (94.1%; 95% CI 93.3 - 94.9) and those on therapy for >120 days (81.1%; 95% CI 80.7 - 81.5) (d>1.0).

Patient compliance with AD therapy
Only 34% of patients were compliant with the AD treatment. In the majority of cases (66%), the MPRs were not in the acceptable range (80 - 110%) and the treatment period was <120 days (Table 3); these patients were therefore deemed non-compliant.

No statistically significant association was found between gender and patient compliance (p=0.1342). Of practical significance (p<0.0001; Cramer V=0.0734), the results reveal that a larger percentage (38.9%) of patients aged >60 years receiving ADs, and who were likely to have chronic comorbidities such as hypertension or diabetes, were compliant compared with those in the 18 - 40 years age group (Table 3).

The ten most dispensed AD medications represented 86.1% of all those dispensed during the study period (Table 1). These include venlafaxine, escitalopram, duloxetine, mirtazapine, citalopram, fluoxetine, bupropion, sertraline, amitriptyline and trazodone. A statistically significant association was found between the type of active ingredients consumed and compliance (p=0.0001) (Table 3). Only 26.2% of patients who received amitriptyline-containing products were compliant compared with 38.8% and 37.8% in the case of the ADs with the highest compliance, viz. venlafaxine and duloxetine, respectively (Table 3).

| Table 1. Patient demographics and medicine use data |
| --- |
| **Age (years), mean (SD)** | 50.4 (15.9) |
| **Age groups (years), n (% of 14 135)** |  |
| >18 - ≤40 | 3 449 (24.4) |
| >40 - ≤60 | 6 537 (46.2) |
| >60 | 4 149 (29.4) |
| **Gender, n (% of 14 135)** |  |
| Female | 10 003 (70.8) |
| Male | 4 132 (29.2) |
| **Treatment period (days), n (% of 14 135)** |  |
| ≤30 | 830 (5.9) |
| >30 - ≤120 | 3 256 (23.0) |
| >120 | 10 049 (71.1) |
| **Top ten active ingredients (medicine items), n (% of 35 175)** |  |
| Venlafaxine | 5 222 (14.9) |
| Escitalopram | 5 117 (14.6) |
| Duloxetine | 3 351 (9.5) |
| Mirtazapine | 2 992 (8.5) |
| Citalopram | 2 919 (8.3) |
| Fluoxetine | 2 433 (6.0) |
| Bupropion | 2 153 (6.1) |
| Sertraline | 2 137 (6.1) |
| Amitriptyline | 2 105 (6.0) |
| Trazodone | 1 834 (5.2) |

| Table 2. MPRs of ADs by age group, gender and treatment period |
| --- |
| **Variable** | **n** | **Mean MPR (%)** | **95% CI** | **p-value** |
| Overall | 35 175 | 98.2 | 96.6 - 99.9 | 0.0169 |
| Age group (years) | 65.9 |  |  |
| >18 - ≤40 | 7 419 | 102.4* | 98.1 - 106.8 |
| >40 - ≤60 | 16 911 | 98.0 | 95.7 - 100.4 |
| >60 | 10 845 | 95.6* | 93.0 - 98.3 |
| Gender | 0.9200 |  |  |
| Male | 9 739 | 98.4 | 95.4 - 101.4 |
| Female | 25 536 | 98.2 | 96.2 - 100.1 |
| Treatment period (days) | 0.0001 |  |  |
| ≤30 | 2 769 | 255.4 | 235.7 - 275.1 |
| >30 - ≤120 | 9 208 | 94.1 | 93.3 - 94.9 |
| >120 | 23 198 | 81.1 | 80.7 - 81.5 |

*Significant difference in mean MPR (p=0.0169).

Changes in PDDs and compliance
Negative correlations between the initial PDD and PDD changes were found for all ADs (p=0.0001), with r̃=−0.5 for venlafaxine, escitalopram, mirtazapine and amitriptyline. Statistically significant
differences \( p<0.05; d<0.8 \) in the adjusted PDD changes were found between complaint and non-compliant patients on venlafaxine, escitalopram, mirtazapine and amitriptyline therapy (Table 4). The adjusted mean decrease of 6.7 mg (95% CI –10.2 - –3.2) in the PDD of venlafaxine in the non-compliant patients was significantly different compared with the mean increase of 1.2 mg (95% CI –3.2 - 5.6) in the compliant patients (Table 4). The PDD of mirtazapine also decreased, with an adjusted mean of 0.2 mg (95% CI –1.2 - –0.06) in the non-compliant patients and 1.2 mg (95% CI 0.3 - 2.0) in the compliant patients (Table 4). The mean adjusted PDD for amitriptyline also decreased, with an adjusted mean of 1.3 mg (95% CI –2.5 - –0.06) in the non-compliant patients and a 1.5 mg (95% CI –0.5 - 3.6) increase in the compliant patients (Table 4). The mean PDD of escitalopram increased more in the compliant patients (1.7 mg; 95% CI 1.2 - 2.2) than in those who were non-compliant (0.1 mg; 95% CI –0.3 - 0.5) from the first prescription to the last prescription (Table 4).

**Discussion**

The most important findings of this study are that: (i) compliance with chronic AD treatment is poor (34%) in the SA private healthcare population; and (ii) use of medicine claims data may be a feasible and reliable way to assess medicine possession ratios and subsequent compliance with ADs.

Non-compliance in patients taking ADs is a major concern. The 34% compliance rate described here is especially poor, although Bambauer et al. found that 42% of patients stopped their treatment within the first 30 days, and by day 90, 72% of patients had done so. Our study not only emphasises that non-compliance is a major obstacle in the successful management of MDD, but to our knowledge demonstrates for the first time that this hindrance to a successful outcome is evident in a middle-income country and is comparable to data reported for developed countries. Interestingly, this observation has prompted studies geared to isolating possible reasons for the poor compliance, such as feeling better, side-effects, fear of addiction and lack of efficacy.

We found the prevalence of MDD in female patients to be almost double that in males, in keeping with previous studies. Stressful life events are implicated in the emergence and persistence of gender differences associated with MDD, and it has been postulated that women have a biological and/or psychological vulnerability towards developing an anxiety or mood disorder.

We have noted earlier that non-compliance

### Table 3. Patient compliance with ADs by age group, gender and active ingredient

| Variable | Compliant | Non-compliant | \( p\)-value |
|----------|-----------|---------------|--------------|
| Overall, n (% of 35 175) | 11 953 (34.0) | 23 222 (66.0) | 0.0001 |
| Age group (years), n (%) | | | |
| >18 - ≤40 | 202/5 419 (29.7) | 5 217/5 419 (70.3) | 0.0001 |
| >40 - ≤60 | 5 534/16 911 (32.7) | 11 377/16 911 (67.3) | 0.0001 |
| >60 | 4 217/10 845 (38.9) | 6 628/10 845 (61.1) | 0.0001 |
| Gender, n (%) | | | 0.1342 |
| Male | 3 369/9 739 (34.6) | 6 370/9 739 (65.4) | |
| Female | 8 584/25 436 (33.8) | 16 852/25 436 (66.3) | |
| Top ten active ingredients, n (%) | 0.0001 |
| Venlafaxine | 2 026/5 222 (38.8) | 3 196/5 222 (61.2) | |
| Escitalopram | 1 796/5 117 (35.1) | 3 321/5 117 (64.9) | |
| Duloxetine | 1 295/3 351 (38.7) | 2 056/3 351 (61.4) | |
| Mirtazapine | 862/2 992 (28.8) | 2 130/2 992 (71.2) | |
| Citalopram | 1 032/2 929 (35.4) | 1 887/2 919 (64.7) | |
| Fluoxetine | 763/2 433 (31.4) | 1 670/2 433 (68.6) | |
| Bupropion | 724/2 153 (33.6) | 1 429/2 153 (66.4) | |
| Sertraline | 701/2 137 (32.8) | 1 436/2 137 (67.2) | |
| Amitriptyline | 552/2 105 (26.2) | 1 553/2 105 (73.8) | |
| Trazodone | 602/1 834 (32.8) | 1 232/1 834 (67.2) | |

### Table 4. PDD adjusted for possible change in initial AD dosage in both compliant and non-compliant patients

| Top ten active ingredients | Compliant patients | Non-compliant patients | Compliant patients | Non-compliant patients |
|---------------------------|---------------------|------------------------|---------------------|------------------------|
|                           | Initial PDD (mg)    | Final PDD (mg)         | Initial PDD (mg)    | Final PDD (mg)         |
| Venlafaxine | 1 986 | 136.1 | 137.2 | 3 179 | 135.9 | 129.3 | 1.2 | –3.2 - 5.6 | –6.7 | –10.2 - –3.2 | 0.006 |
| Escitalopram | 1 796 | 20.7 | 21.9 | 3 321 | 19.7 | 20.1 | 1.7 | 1.2 - 2.2 | 0.1 | –0.3 - 0.5 | 0.0001 |
| Duloxetine | 1 295 | 60.7 | 61.8 | 2 056 | 56.3 | 57.3 | 3.9 | 2.0 - 5.9 | 1.7 | 0.1 - 3.2 | 0.08 |
| Mirtazapine | 862 | 26.3 | 26.3 | 2 126 | 25.1 | 24.7 | 1.2 | 0.3 - 2.0 | –0.2 | –1.2 - –0.06 | 0.0007 |
| Citalopram | 1 012 | 26.5 | 29.1 | 1 871 | 28.7 | 29.1 | 2.4 | 1.5 - 3.3 | 1.5 | 0.8 - 2.2 | 0.12 |
| Fluoxetine | 731 | 32.9 | 33 | 1 654 | 33 | 33.1 | 0.8 | –0.5 - 2.1 | 0.5 | –0.4 - 1.4 | 0.76 |
| Bupropion | 724 | 235 | 242.8 | 1 429 | 238.6 | 246.7 | 27.0 | 11.2 - 42.8 | 26.8 | 16.5 - 37.1 | 0.98 |
| Sertraline | 675 | 78.7 | 82.6 | 1 418 | 80.5 | 84.4 | 5.8 | 3.6 - 8.1 | 5.7 | 4.1 - 7.2 | 0.90 |
| Amitriptyline | 522 | 43.2 | 43.3 | 1 553 | 40.6 | 37.9 | 1.5 | –0.5 - 3.6 | –1.3 | –2.5 - –0.06 | 0.02 |
| Trazodone | 602 | 274.6 | 284.2 | 1 232 | 390.7 | 362.5 | –13.9 | –34.8 - 7.0 | 4.2 | –10.4 - 18.8 | 0.16 |
and inappropriate discontinuation evoke a stress response that may adversely affect long-term outcomes.[21,22] It could also be argued that males would be more likely to discontinue their AD medication voluntarily, owing to a stronger negative bias associated with the psychological stigma of the illness. However, we did not observe any significant association between compliance and gender. Two earlier studies have also noted that the gender of ambulatory patients treated with AD is a weak predictor of non-compliance.[23,24]

Our study also reveals that elderly patients (>60 years) may be more compliant than younger populations taking ADs. In fact, elderly patients demonstrate reduced dropout ratios and are more likely to comply with their medication, and in some cases respond better to treatment, than younger patients.[25] Younger patients have a stronger negative bias towards issues such as weight gain, sexual dysfunction and dissatisfaction with the physician.[26,27]

We also demonstrated that the treatment period has a definite influence on the MPR and patient compliance. We found that patients were prescribed an oversupply of AD during the first month of treatment. This is an interesting observation, especially since giving excessive medication may constitute a risk in patients with suicidal ideation. However, issues of dosage instability, side-effects and changing the regimen or dosage may explain this observation. Moreover, hospitalisation and co-prescription of medicines may also occur. These findings should be considered when calculating the MPR as a measure of patient compliance, taking into account that patients on AD treatment first need to be stabilised on the correct AD and dose. However, it is of great concern that patients become gradually less compliant in the latter part of the 4-month treatment period.

The serotonin re-uptake inhibitors (SSRIs), represented here by escitalopram, citalopram, fluoxetine and sertraline, are first-line treatments for MDD because of improved safety and reduced cost,[28] and are the most frequently dispensed class of ADs for this disorder.[29]

Furthermore, in the SA private health sector they have compliance rates of between 32.8% and 34% (this study), which is slightly higher than the 25.5% reported elsewhere.[42] The low compliance with SSRIs in this study population is a noteworthy observation. We found compliance ratios for venlafaxine and duloxetine to be significantly better (p<0.001) (38.8% and 38.7%) than that for amitriptyline (26.2%). Amitriptyline was found to have the worst compliance, perhaps because of its greater side-effect burden.[43,44] A negative correlation was found between the initial PDD and the change in PDD, implying that the higher the initial PDD the smaller the change in PDD, particularly for venlafaxine, escitalopram, mirtazapine and amitriptyline. A higher initial PDD was also associated with better compliance with AD treatment. This finding is supported in the literature, as several studies have found that MDD is commonly treated with inadequate doses of ADs.[40,46,47] Furthermore, a study by Marcus et al.[48] found that a lower initial dose of AD was associated with subsequent switching to another AD or to an entirely new class of AD, suggesting that an inadequate dose at the start of treatment may contribute to a suboptimal response to initial AD treatment and therefore increase the possibility of AD switching and relapse.

Conclusion

We established that compliance with AD treatment remains a major obstacle in the treatment of MDD in a middle-income developing country like SA. These findings are worrying, as such non-compliance may have significant negative effects not only on the long-term treatment outcome of MDD but also that of comorbid disorders. Some of these aspects are currently under study by our research group. We found that only a third of patients suffering from MDD are compliant with their AD treatment, with newer-generation ADs (particularly serotonin noradrenaline reuptake inhibitors (SNRIs)) performing better. We also verified that data from medicine claims may be used as a measure of patient compliance in the clinical setting. Furthermore, the treatment period has a statistically significant effect on the MPR when used as a measure of compliance.

Conflict of interest. BHH has participated in speakers/advisory boards and received honoraria from Organon, Pfizer and Servier, and has received research funding from Lundbeck and Servier. Except for income from the primary employer and research funding to BHH from the SA Medical Research Council, and the exceptions noted earlier, no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional services, and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.

Acknowledgements. We thank Dr Suria Ellis from Statistical Consultation Services, North-West University, Potchefstroom Campus, for statistical support, and Anne-Marie Bekker for administrative support regarding the database. The authors thank North-West University, the National Research Foundation and the South African Medical Research Council for financial support.

References

1. Tomlinson M, Grimmel AT, Stein DJ et al. The epidemiology of major depression in South Africa: Results from the South African stress and health study. S Afr Med J 2009;99(3):367-373.
2. Kosler BC, Chin WF, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):617-627.
3. Alonso J, Angermeyer MC, Bernert S, et al. Disability and quality of life impact of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Physiol Scand 2004;181(Suppl 620):36-46.
4. Gooren LJ, Jamesium KB. Suicide in manic-depressive illness. New York: Oxford University Press, 1995:227-244.
5. Andlin-Sobrock P, Jernom S, Witschon HH et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl 1):1-27. [http://dx.doi.org/10.1111/j.1468-1331.2005.01285.x]
6. National Institute of Mental Health. The numbers count: Mental disorders on America. 2011. [http://www.nimh.nih.gov/health/publications/the-numbers-count-mental-illnesses-in-america/index.shtml#inFocus (accessed 15 June 2012).
7. Lamel C, Nyer L, Stein DJ et al. Mental illness and lost income among adult South Africans. Soc Psychiatr Epidemiol 2013;48(5):845-851. [http://dx.doi.org/10.1007/s00127-012-0587-5]
8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353(5):487-497. [http://dx.doi.org/10.1056/NEJMra040190]
9. National Institute for Health and Clinical Excellence. Depression: The treatment and management of depression in adults. Partial update of NICE clinical guideline 2009. [http://www.nice.org.uk/nicemedia/pdf/CG003NICEguideline.pdf (accessed 2 May 2013).
10. Keller MB, Hirschfeld RM, Dennehey K et al. Optimising outcomes in depression: Focus on antidepressant compliance. J Clin Psychopharmacol 2002;22(3):245-251.
11. Akrabadi AC, Bengtsen E, von Knorring L et al. Response, remission and relapse in relation to adherence in primary care treatment of depression: A 2-year outcome study. J Clin Psychopharmacol 2006;26(2):127-134.
12. Akrabadi AC, Bengtsen E, Holgermen M et al. Identification of primary care patients at risk of non-adherence to antidepressant treatment. Patient Prefer Adherence 2008;2:379-386.
13. Godfrey JR, Carney SM, Dorves C et al. Relapse prevention with antidepressant drug treatment in depressions disorders: A systematic review. Lancet 2003;363(9402):855-861. [http://dx.doi.org/10.1016/S0140-6736(03)12999-8]
14. Serna MC, Cruz I, Real J et al. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry 2010;25(6):206-215. [http://dx.doi.org/10.1016/j.eurpsy.2009.07.012]
15. Denneyehr K. Compliance during treatment with antidepressants. J Affect Disord 1997;43(1):27-39. [http://dx.doi.org/10.1016/S0165-0327(96)00095-3]
16. Cramer JA. Optimizing long-term patient compliance. Neurology 1995;45(2 Suppl 1):S25-S28.
17. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRI's and tricyclic antidepressants: A meta-analysis and reevaluation of heterogeneity. Br J Psychiatry 1997;170:120-127. [http://dx.doi.org/10.1192/brjp.170.2.120]
18. Lin EH, von Korff M, Karen W et al. The role of the primary care physician in patients’ adherence to antidepressant therapy. Med Care 1995;33(1):67-74. [http://dx.doi.org/10.1097/00005656-199501000-00006]
19. Robinson P, Bruni L, von Korff M et al. Primary care physician use of cognitive behavioral techniques with depressed patients. J Fam Pract 1995;40(6):352-357.
20. Frank E, Perel JM, Mallinger AG et al. Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression. Psychopharmacol Bull 1992;28(3):231-235.
21. Harvey RH, McWhinney BS, Stein DJ. Neurobiology of antidepressant withdrawal: Implications for prophylaxis in recurrent depression. Psychopharmacol Bull 1992;28(3):231-235.
22. Harvey RH. Adaptive plasticity during stress and depression and the role of glutamate-nitric oxide pathways. S Afr Psychiatry Rev 2006;13:139. [http://www.nicemedia/pdf/CG003/CG003.pdf (accessed 27 December 2014).
23. MIMS: Monthly Index of Medical Specialities 2012,3(2):13-28.
24. World Health Organization. ICD-10 Version. 2010. [http://apps.who.int/classifications/icd10/browsenew/2010/en (accessed 23 November 2012)].
25. Cramer JA, Benokraitis N, Mandoki L, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidemia: A review. Int J Clin Pract 2008;62(1):76-87. [http://dx.doi.org/10.1111/j.1742-1241.2007.01630.x]
26. Weidner D, Macario A, Zbildung J, et al. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007;18(3):271-277. [http://dx.doi.org/10.1007/s00198-006-0259-y]
27. Weiden PJ, Korza C, Grego A, et al. Partial compliance and risk of hospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55(8):866-871. [http://dx.doi.org/10.1176/appi.ps.55.8.866]
28. Peterson DL, Benkelfat C, Mohr J, et al. Adherence to triple inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133(1):31-36. [http://dx.doi.org/10.7326/0003-4819-133-1-20000740-00004]
29. Steiner JF, Prochaska JO. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 1997;50(11):103-110. [http://dx.doi.org/10.1016/S0895-4356(96)00226-5]
30. Steyn HS. Manual for the Determination of Effect Size Indices and Practical Significance. Potchefstroom: North-West University; http://www.nwu.ac.za/content/states-effect-size (accessed 25 September 2012).
31. Bambauer KZ, Adams AS, Zhang F, et al. Physician alerts to increase antidepressant adherence: Fact or fiction? Arch Intern Med 2006;166(5):498-504. [http://dx.doi.org/10.1001/archinte.166.5.498]
32. Demyttenaere K, Egede LE, Lewiecki EM, et al. Compliance with antidepressants in a primary care setting. 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(Suppl 2):30-33.
33. Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression. Psychiatr Serv 2009;60(5):617-623. [http://dx.doi.org/10.1176/appi.ps.60.5.617]
34. Kessler RC. Epidemiology of women and depression. J Affect Disord 2003;74(1):5-13. [http://dx.doi.org/10.1016/S0165-0327(02)00426-3]
35. Harvey BH, Hamer M, Louw R, et al. Metabolic and glutathione redox markers associated with brain-derived neurotrophic factor in depressed African men and women: Evidence for counterregulation? Neuropsychobiology 2013;67(1):33-40. [http://dx.doi.org/10.1159/000343501]
36. Hankin BL, Abramson LY. Development of gender differences in depression: An elaborated cognitive vulnerability-transactional stress theory. Psychol Bull 2001;127(6):774-796. [http://dx.doi.org/10.1037//0033-2909.127.6.774]
37. Simon GE, Von Korff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1999;21(5):399-408.
38. Barer RB, Vemuri SP. Depression in later life: A diagnostic and therapeutic challenge. Am Fam Physician 2004;69(10):2375-2382.
39. Akincigil A, Bozbas B, Levin C, et al. Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Med Care 2007;45(4):363-369. [http://dx.doi.org/10.1097/01.mdc.0000254754.24184.6e]
40. Tamberierno RD, Nagai BH, Chaudhry B, et al. Antidepressant medication adherence: A study of primary care patients. J Clin Psychiatry 2009;70(9):205-211. [http://dx.doi.org/10.4088%2FJCP.880094]
41. Gelenberg AJ, Freeman MP, Markowitz JC, et al. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. 2010. http://www.psychiatryonline.com/pracGuide/pracGuideTopics_7.aspx (accessed 17 July 2013).
42. Liu S, Chen Y, Furtt DE. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Clinicoecon Outcomes Res 2011;3(1):63-72. [http://dx.doi.org/10.2147%2FCEOR.S117846]
43. Baldwin DS. Unmet needs in the pharmacological management of depression. Hum Psychopharmacol Clin Exp 2011;26(4):S93-599. [http://dx.doi.org/10.1002/spe.337]
44. Hirschfeld RM. Antidepressants in long-term therapy: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000;154(S403):35-38. [http://dx.doi.org/10.11151.1600-0447.2000.03403.5-38]
45. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25(8):2289-2304. [http://dx.doi.org/10.1016/S0149-2918(03)80220-5]
46. Dew RE, Kramer SL, McCaff WV. Adequacy of antidepressant treatment by psychiatric residents: The antidepressant treatment history form as a possible assessment tool. Acad Psychiatry 2005;29(3):283-288. [http://dx.doi.org/10.1176/appi.ap.29.3.283]
47. Mulsant BH, Hackett JG, Pandia J, et al. Low use of nonopioid drugs in the treatment of psychiatric major depression. Am J Psychiatry 1997;154(4):559-561. [http://app.psychiatryonline.com/docs/pdfsplus/10.1176/appi.154.4.559]
48. Shauna M, Lyons JS, O’Malley MT, Rosenberg A, Miller SI, Howard KI. Serotonin reuptake inhibitors and the adequacy of antidepressant treatment. Int J Psychiatry Med 1997;27(2):83-92. [http://dx.doi.org/10.1177/0020745X970270202020-5]
49. Marcus SC, Hassan M, Olfson M. Antidepressant switching among adherent patients treated for depression. Psychiatr Serv 2009;60(5):617-623. [http://dx.doi.org/10.1176/appi.ps.60.5.617]

Accepted 22 October 2014.